Tuberculosis is a pandemic, chronic infectious disease which affects more than 10 million people in the world. About 3.5% of patients of newly diagnosed have reported having multidrug-resistant tuberculosis (MDR-TB). The standard treatment of MDR-TB has many cons like high cost, less effectiveness, and more drug interactions. Thus, to overcome these disadvantages a new novel compound which belongs to the diarylquinolone group called bedaquiline has been developed as a part of combination therapy in adults with MDR-TB for its bactericidal activity. It mainly acts by inhibiting the adenosine triphosphate synthase enzyme of Mycobacterium tuberculosis. This drug was introduced as a new addition to the standard TB regimen after 50 years.
Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163(9): 1009–1021. DOI: 10.1001/archinte.163.9.1009.
Young DB, Perkins MD, Duncan K, Barry 3rd CE. Confronting the scientific obstacles to global control of tuberculosis. J Clin Invest 2008;118(4):1255–1265. DOI: 10.1172/JCI34614.
Sandhu GK. Tuberculosis: current situation, challenges and overview of its control programs in India. J Glob Infect Dis 2011;3(2):143–150. DOI: 10.4103/0974-777X.81691.
Nagabushan H, Roopadevi HS. Bedaquiline: a novel antitubercular drug for multidrug-resistant tuberculosis. J Postgrad Med 2014;60(3):300–302. DOI: 10.4103/0022-3859.138772.
WHO. Global Tuberculosis Report 2014, vol. 5 Geneva: World Health Organisation; 2014; 54 p. 54.
Deoghare S. Bedaquiline: a new drug approved for treatment of multidrug resistant tuberculosis. Indian J Pharmacol 2013;45(5): 536–537. DOI: 10.4103/0253-7613.117765.
Lienhardt C, Nahid P, Rich ML, Bansbach C, Kendall EA, Churchyard G, et al. Target regimen profiles for treatment of tuberculosis: a WHO document. Eur Respir J 2017;49(1):1602352. DOI: 10.1183/13993003.02352-2016.
Gualano G, Capone S, Matteelli A, Palmieri F. New antituberculosis drugs: from clinical trial to programmatic use. Infect Dis Rep 2016;8(2):6569. DOI: 10.4081/idr.2016.6569.
Yadav S, Rawal G, Baxi M. Bedaquiline: a novel antitubercular agent for the treatment of multidrug resistant tuberculosis. J Clin Diagn Res 2016;10(8):FM01–FM02. DOI: 10.7860/JCDR/2016/19052.8286.
Kakkar AK, Dahiya N. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls. Tuberculosis (Edinb) 2014;94(4):357–362. DOI: 10.1016/j.tube.2014.04.001.
Singh A, Prakash V, Kant S, Kumar R, Bhatia A, Verma AK, et al. Bedaquiline: a new hope in treatment of tuberculosis. Int J Health Allied Sci 2016;5(3):172–173. DOI: 10.4103/2278-344X.187830.
Lenaerts AJ, Hoff D, Aly S, Ehlers S, Andries K, Cantarero L, et al. Location of persisting mycobacteria in a guinea pig model of tuberculosis revealed by r207910. Antimicrob Agents Chemother 2007;51(9):3338–3345. DOI: 10.1128/AAC.00276-07.
Veziris N, Ibrahim M, Louis N, Chauffour A, Truffot-Pernot C, Andries K, et al. A once weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am J Respir Crit Care Med 2009;179(1):75–79. DOI: 10.1164/rccm.200711-1736OC.
Ibrahim M, Andries K, Lounis N, Chauffour A, Truffot-Pernot C, Jarlier V, et al. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother 2007;51(3):1011–1015. DOI: 10.1128/AAC.00898-06.
Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother 2003;52(5):790–795. DOI: 10.1093/jac/dkg446.
Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009;360(23):2397–2405. DOI: 10.1056/NEJMoa0808427.
Diacon AH, Pym A, Grobusch M, de los Rios JM, Gotuzzo E, Vasilyeva I, et al. Multidrug resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014;371(8):723–732. DOI: 10.1056/NEJMoa1313865.
Guglielmetti L, Le Du D, Jachym M, Henry B, Martin D, Caume E, et al. Compassionate use of bedaquiline for the treatment of multidrug resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis 2015;60(2):188–194. DOI: 10.1093/cid/ciu786.
Ndjeka N, Conradie F, Schnippel K, Hughes J, Bantubani N, Ferreira H, et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int J Tuberc Lung Dis 2015;19(8):979–985. DOI: 10.5588/ijtld.14.0944.
Pym AS, Diacon H, Tang S-J, Francesca C, Manfred D, Charoen C, et al. Bedaquiline in the treatment of multidrug and extensively drug resistant tuberculosis. Eur Respir J 2016;47(2):564–574. DOI: 10.1183/13993003.00724-2015.
Tsuyuguchi K, Sasaki Y, Mitarai S, Kurosawa K, Saito Y, Koh T. Safety, efficacy, and pharmacokinetics of bedaquiline in Japanese patients with pulmonary multidrug resistant tuberculosis: an interim analysis of an open-label, phase 2 study. Respir Investig 2019;57(4):345–353. DOI: 10.1016/j.resinv.2019.01.001.
Guglielmetti L, Jaspard M, Le Dû D, Marie L, Dhiba M-O, Christine B, et al. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J 2017;49(3):1601799. DOI: 10.1183/13993003.01799-2016.
Borisoy SE, D'Ambrosio L, Centis R, Tiberi S, Dheda K, Alffenaar JW, et al. Outcomes of patients with drug resistant tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery. J Infect 2019;78(1):35–39. DOI: 10.1016/j.jinf.2018. 08.003.
Telnov O, Alvarez V, Graglia E, Molfino L, Cros PD, Rich M. Bedaquiline overdose: a case report. Int J Infect Dis 2019;84:138–140. DOI: 10.1016/j.ijid.2019.03.035.
Lu X, Smare C, Kambili C, Khoury ACE, Wolfson LJ. Health outcomes of bedaquiline in the treatment of multidrug resistant tuberculosis in selected high burden countries. BMC Health Serv Res 2017;17(1):87. DOI: 10.1186/s12913-016-1931-3.
Park S, Lee KM, Kim I, Mok J. The use of bedaquiline to treat patients with multidrug-resistant tuberculosis and end stage renal disease: a case report. Indian J Infect Dis 2018;76:88–90. DOI: 10.1016/j.ijid.2018.09.009.
U.S. Food and Drug Administration. SIRTURO Prescribing Information 2013. pp. 1–25.
Fox GJ, Menzies D. A review of the evidence for using bedaquiline (TMC207) to treat multidrug resistant tuberculosis. Infect Dis Ther 2013;2(2):123–144. DOI: 10.1007/s40121-013-0009-3.
Matteelli A, Carvalho ACC, Dooley KE, Kritski A. TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol 2010;5(6):849–858. DOI: 10.2217/fmb.10.50.
Field SK. Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment? Ther Adv Chronic Dis 2015;6(4):170–184. DOI: 10.1177/2040622315582325.
Lounis N, Gevers T, Van Den Berg J, Andries K. Impact of the interaction of R207910-with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob Agents Chemother 2008;52(10): 3568–3572. DOI: 10.1128/AAC.00566-08.
Koul A, Vranckx L, Dendouga N, Balemans W, Van den Wyngaert I, Vergauwen K, et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem 2008;283(37):25273–25280. DOI: 10.1074/jbc.M803899200.
Gelber R, Andries K, Paredes RM, Andaya CE, Burgos J. The diarylquinolone R207910 is bactericidal against Mycobacterium lepraein mice at low dose and administered intermittently. Antimicrob Agents Chemother 2009;53(9):3989–3991. DOI: 10.1128/AAC.00722-09.
World Health Organisation. WHO treatment guidelines for multi drug and rifampicin resistant tuberculosis 2018 update.
World Health Organisation. WHO best practice statement on the off label use of Bedaquiline and Delamanid for the treatment of multidrug resistant tuberculosis. 2017.
